Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

August 23rd 2024

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts

August 22nd 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

Sacituzumab Govitecan Displays Activity in Advanced/Metastatic Endometrial Cancer

August 19th 2024

Treatment with sacituzumab govitecan led to antitumor activity in endometrial cancer and TROP-2 expression did not appear to affect response to the agent.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Pirtobrutinib Displays Efficacy in Patients With Richter Transformation

August 15th 2024

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Analyzing the “RAS Pie” for Methods to Target Mutations in GI Cancers

August 14th 2024

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Cannabis-Use Disorder Demonstrates a Link With Developing Head and Neck Cancer

August 14th 2024

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia

August 12th 2024

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11th 2024

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Research Across 5 Sarcoma Stem Cell Subtypes Identifies EZH2 as a Potential Therapeutic Target

August 9th 2024

R. Lor Randall, MD, FACS, details findings from a genetic and epigenetic study showing 5 sarcoma subtypes had EZH2 activity and a shared epigenetic profile.

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 8th 2024

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL

August 7th 2024

The combination of ibrutinib, lenalidomide, and rituximab elicited a high response rate in patients with relapsed/refractory mantle cell lymphoma.

Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC

August 7th 2024

East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.

IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma

August 6th 2024

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.

Chemotherapy-Free Approaches Are at the Forefront in MCL

August 5th 2024

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.